HomeCompareABT vs EMN

ABT vs EMN: Dividend Comparison 2026

ABT yields 2.36% · EMN yields 4.60%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABT wins by $471.1K in total portfolio value· pulled ahead in Year 4
10 years
ABT
ABT
● Live price
2.36%
Share price
$101.89
Annual div
$2.40
5Y div CAGR
63.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$533.6K
Annual income
$328,772.04
Full ABT calculator →
EMN
EMN
● Live price
4.60%
Share price
$72.55
Annual div
$3.34
5Y div CAGR
25.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$62.5K
Annual income
$11,712.17
Full EMN calculator →

Portfolio growth — ABT vs EMN

📍 ABT pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodABTEMN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ABT + EMN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ABT pays
EMN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ABT
Annual income on $10K today (after 15% tax)
$200.23/yr
After 10yr DRIP, annual income (after tax)
$279,456.23/yr
EMN
Annual income on $10K today (after 15% tax)
$391.32/yr
After 10yr DRIP, annual income (after tax)
$9,955.34/yr
At 15% tax rate, ABT beats the other by $269,500.89/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ABT + EMN for your $10,000?

ABT: 50%EMN: 50%
100% EMN50/50100% ABT
Portfolio after 10yr
$298.1K
Annual income
$170,242.11/yr
Blended yield
57.11%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABT right now

ABT
Analyst Ratings
30
Buy
10
Hold
Consensus: Buy
Price Target
$137.67
+35.1% upside vs current
Range: $120.00 — $158.00
Altman Z
4.9
Piotroski
6/9
EMN
Analyst Ratings
20
Buy
14
Hold
1
Sell
Consensus: Buy
Price Target
$74.00
+2.0% upside vs current
Range: $70.00 — $79.00
Altman Z
2.3
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ABT buys
0
EMN buys
0
No recent congressional trades found for ABT or EMN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricABTEMN
Forward yield2.36%4.60%
Annual dividend / share$2.40$3.34
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR63.2%25.7%
Portfolio after 10y$533.6K$62.5K
Annual income after 10y$328,772.04$11,712.17
Total dividends collected$492.4K$36.8K
Payment frequencyquarterlyquarterly
SectorHealthcareMaterials
Analyst consensusBuyBuy
Analyst price target$137.67$74.00

Year-by-year: ABT vs EMN ($10,000, DRIP)

YearABT PortfolioABT Income/yrEMN PortfolioEMN Income/yrGap
1$11,084$384.43$11,279$578.69$195.00EMN
2$12,510$649.94$12,835$766.75$325.00EMN
3$14,505$1,118.82$14,758$1,025.04$253.00EMN
4← crossover$17,499$1,978.53$17,176$1,384.65+$323.00ABT
5$22,364$3,640.59$20,272$1,893.11+$2.1KABT
6$31,026$7,096.70$24,315$2,624.76+$6.7KABT
7$48,215$15,016.56$29,716$3,698.58+$18.5KABT
8$87,182$35,592.30$37,106$5,310.02+$50.1KABT
9$191,446$98,161.15$47,493$7,789.38+$144.0KABT
10$533,619$328,772.04$62,530$11,712.17+$471.1KABT

ABT vs EMN: Complete Analysis 2026

ABTHealthcare

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Full ABT Calculator →

EMNMaterials

Eastman Chemical Company operates as a specialty materials company in the United States and internationally. The company's Additives & Functional Products segment offers hydrocarbon and rosin resins; organic acid-based solutions; amine derivative-based building blocks; metam-based soil fumigants, thiram and ziram based fungicides, and plant growth regulators; specialty coalescent, specialty and commodity solvents, paint additives, and specialty polymers; heat transfer and aviation fluids; insoluble sulfur and anti-degradant rubber additives; and performance resins. It serves transportation, personal care, wellness, food, feed, agriculture, building and construction, water treatment, energy, consumables, durables, and electronics markets. Its Advanced Materials segment provides copolyesters, cellulosic biopolymers, cellulose esters, polyvinyl butyral (PVB) sheets, and window and protective films, and aftermarket applied film products for value-added end uses in the transportation, durables, electronics, building and construction, medical and pharma, and consumables markets. The company's Chemical Intermediates segment offers methylamines and salts higher amines and solvents; Olefin and acetyl derivatives, ethylene, and commodity solvents; and primary non-phthalate and phthalate plasticizers, and niche non- phthalate plasticizers to the industrial chemicals and processing, building and construction, health and wellness, and agrochemicals. Its Fibers segment provides cellulose acetate tow, triacetin, cellulose acetate flake, acetic acid, and acetic anhydride for use in filtration media primarily cigarette filters; natural and solution dyed acetate yarns for use in consumables, and health and wellness markets; and wet-laid nonwoven media, specialty and engineered papers, and cellulose acetate fibers for transportation, industrial, agriculture and mining, and aerospace markets. Eastman Chemical Company was founded in 1920 and is headquartered in Kingsport, Tennessee.

Full EMN Calculator →
📬

Get this ABT vs EMN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ABT vs SCHDABT vs JEPIABT vs OABT vs KOABT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.